ARTICLE

A DEEP INSIGHT ON RHEUMATOID ARTHRITIS INDEXES DISEASE ACTIVITY SCORE

  1. HOME
  2. ARTICLE

01 Pages : 1-8

http://dx.doi.org/10.31703/giidr.2020(V-I).01      10.31703/giidr.2020(V-I).01      Published : Dec 2020

A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a

Abstract

    Rheumatoid arthritis as one of the autoimmune diseases is more prevalent now than ever before. Being more common in women than men, RA has been focused by researchers to invent a therapeutic agent for effective clinical response. Various Diagnostic biomarkers are being used for early diagnosis of RA depending upon their selectivity and specificity. Certain indexes for RA disease activity evaluation are used for assessment of disease on a continuous scale. Disease activity Score combined with laboratory data result and imaging technologies makes the decision of treatment strategies easier than before. Traditionally, TNFi are the most used agents since a decade and first choice of treatment by clinicians, however, combination therapy with DMARD is used in inadequate responders. Despite all the advancements in treatment of RA and proved remission possibility using latest biological agents, studies are needed to ensure quick clinical outcomes and remission probability in larger fraction of people.

    Rheumatoid Arthritis, TNFi, DAS28, Anti - CCP, IL - 17A

    (1) Syed Faaez Ul Hassan Naqvi
    Undergraduate Student, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan.
    (2) Gul Shehnaz
    Chairperson, Department of Pharmacy, Faculty of Biological Sciences, Quaid I Azam University, Islamabad, Pakistan. (Corresponding Author)
Fulltext PDF

References

  • Almaliotis, D., Zakalka, M., Gerofotis, A., Chatzicharalampous, K., Efstathiou, M., Daniilidis, M., & Karampatakis, V. (2016). Ocular Manifestations in Rheumatoid Arthritis. Open Journal of Ophthalmology, 06, 170-175. doi:10.4236/ojoph.2016.63024
  • Ananthathandavan, P., & Vijayakumar, T. (2020). Safety and Efficacy of newer biologics DMARDs in the management of Rheumatoid Arthritis: A Systematic Review. Osteoarthritis and Cartilage Open, 2. doi:10.1016/j.ocarto.2020.100116
  • Ebel, A., & O'Dell, J. (2021). Clinical Features, Diagnosis, and Treatment of Rheumatoid Arthritis. Physician Assistant Clinics, 6, 41-60. doi:10.1016/j.cpha.2020.08.004
  • Harpreet Kaur, J. S. (2012). Diagnostic Biomarkers in Rheumatoid arthritis - An update. Der pharmacia sinica, 408-412.
  • Kay, J., & Upchurch, K. (2012). ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology, 51, vi5-vi9. doi:10.1093/rheumatology/kes279
  • Keystone, E., Curtis, J., Fleischmann, R., Furst, D., Khanna, D., Smolen, J., . . . Combe, B. (2011). Rapid Improvement in the Signs and Symptoms of Rheumatoid Arthritis Following Certolizumab Pegol Treatment Predicts Better Longterm Outcomes: Post-hoc Analysis of a Randomized Controlled Trial. The Journal of rheumatology, 38, 990-996. doi:10.3899/jrheum.100935
  • Keystone, E. C. (2011). Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. J Rheumatol, 38(8), 1552-1562. doi:10.3899/jrheum.100995
  • Launois, R., Avouac, B., Berenbaum, F., Blin, O., Bru, I., Fautrel, B., . . . Combe, B. (2011). Comparison of Certolizumab Pegol with Other Anticytokine Agents for Treatment of Rheumatoid Arthritis: AMultiple-treatment Bayesian Metaanalysis. The Journal of rheumatology, 38, 835-845. doi:10.3899/jrheum.100665
  • Liao, K., & Bykerk, V. (2011). All That Glitters Is Not Gold - Standardizing Diagnosis in Rheumatoid Arthritis Studies. The Journal of rheumatology, 38, 1223-1224. doi:10.3899/jrheum.110466
  • Medeiros, M. M., de Oliveira, B. M., de Cerqueira, J. V., Quixadá, R. T., & de Oliveira Í, M. (2015). Correlation of rheumatoid arthritis activity indexes (Disease Activity Score 28 measured with ESR and CRP, Simplified Disease Activity Index and Clinical Disease Activity Index) and agreement of disease activity states with various cut-off points in a Northeastern Brazilian population. Rev Bras Reumatol, 55(6), 477-484. doi:10.1016/j.rbr.2014.12.
  • Pope, J., & Combe, B. (2013). Unmet Needs in the Treatment of Rheumatoid Arthritis. Open Journal of Rheumatology and Autoimmune Diseases, 03, 65-78. doi:10.4236/ojra.2013.32011
  • Tosh, J., Wailoo, A., Scott, D., & Deighton, C. (2011). Cost-Effectiveness of Combination Nonbiologic Disease-Modifying Antirheumatic Drug Strategies in Patients with Early Rheumatoid Arthritis. The Journal of rheumatology, 38, 1593- 1600. doi:10.3899/jrheum.101327
  • van Vollenhoven, R., Emery, P., Bingham, C., Keystone, E., Fleischmann, R., Furst, D., . . . Rao, R. (2010). Longterm Safety of Patients Receiving Rituximab in Rheumatoid Arthritis Clinical Trials. The Journal of rheumatology, 37, 558-567. doi:10.3899/jrheum.090856
  • Yamasaki, T., Oda, R., Imai, K., Taniguchi, D., Toyama, S., Seno, T., . . . Kubo, T. (2016). Efficacy of MRP8/14 as a Marker of Disease Activity in Rheumatoid Arthritis. Open Journal of Rheumatology and Autoimmune Diseases, 06, 34-39. doi:10.4236/ojra.2016.62006

Cite this article

APA

    APA : Naqvi, S. F. U. H., & Shehnaz, G. (2020). A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a. Global Immunological & Infectious Diseases Review, V(I), 1-8. https://doi.org/10.31703/giidr.2020(V-I).01

CHICAGO

    CHICAGO : Naqvi, Syed Faaez Ul Hassan, and Gul Shehnaz. 2020. "A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a." Global Immunological & Infectious Diseases Review, V (I): 1-8 doi: 10.31703/giidr.2020(V-I).01

HARVARD

    HARVARD : NAQVI, S. F. U. H. & SHEHNAZ, G. 2020. A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a. Global Immunological & Infectious Diseases Review, V, 1-8.

MHRA

    MHRA : Naqvi, Syed Faaez Ul Hassan, and Gul Shehnaz. 2020. "A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a." Global Immunological & Infectious Diseases Review, V: 1-8

MLA

    MLA : Naqvi, Syed Faaez Ul Hassan, and Gul Shehnaz. "A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a." Global Immunological & Infectious Diseases Review, V.I (2020): 1-8 Print.

OXFORD

    OXFORD : Naqvi, Syed Faaez Ul Hassan and Shehnaz, Gul (2020), "A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a", Global Immunological & Infectious Diseases Review, V (I), 1-8

TURABIAN

    TURABIAN : Naqvi, Syed Faaez Ul Hassan, and Gul Shehnaz. "A Deep Insight on Rheumatoid Arthritis, Indexes (Disease Activity Score 28 (DAS28), ESR, CRP, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Global Health) a." Global Immunological & Infectious Diseases Review V, no. I (2020): 1-8. https://doi.org/10.31703/giidr.2020(V-I).01